|Articles|June 1, 2002
First-line therapy: Latanoprost approved for glaucoma use in Europe
Peapack, NJ-Regulatory authorities governing Europe's Mutual Recognition Process have approved the use of latanoprost ophthalmic solution (Xalatan) as a first-line treatment for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























